300753 Jiangsu Apon Medical Technology
- 11.96
- +0.11+0.93%
Jiangsu Apon Medical Technology News
Aipon Healthcare (300753.SZ) 2023 annual equity distribution: 0.65 yuan for every 10 shares, share registration on May 31
Aipon Healthcare (300753.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's total...
Express News | Aipon Healthcare: The company decided to launch the “Protect Nasal Health · Aipon Healthcare Shareholder Reward Campaign”
Brain-computer interface concept stocks fluctuated and fell. Guanhao Biotech fell more than 8%, Sanbo Neurology and Aibang Medical fell more than 6%, and Innovative Healthcare and Shengxun Co., Ltd. followed suit.
Brain-computer interface concept stocks fluctuated and fell. Guanhao Biotech fell more than 8%, Sanbo Neurology and Aibang Medical fell more than 6%, and Innovative Healthcare and Shengxun Co., Ltd. followed suit.
Aipeng Healthcare (300753.SZ) increased their holdings by 558,600 shares in total after half of the increase period
Aipeng Healthcare (300753.SZ) announced that some of the company's directors and senior management plans to increase their share holdings are over half of the time...
Express News | Aipeng Medical reached a strategic collaboration with Shanghai Pharmaceutical Medical Devices
Aipon Healthcare (300753.SZ): Net profit of 1,356.95 million yuan in the first quarter increased 11.63% year-on-year
On April 25, Ge Longhui | Aipeng Healthcare (300753.SZ) released its report for the first quarter of 2024. The operating income for the reporting period was 87.752.96 million yuan, down 6.71% year on year; net profit attributable to shareholders of listed companies was 1,356.95 million yuan, up 11.63% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,7202 million yuan, an increase of 76.41% year on year; basic earnings per share were 0.0108 yuan.
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
Aipon Medical (300753.SZ): Pain products can be used in the nursing market to relieve patients' pain
Gelonghui, March 29丨Aipeng Medical (300753.SZ) said on the investor interactive platform that the company's pain products can all be used in the pension market to relieve patients' pain. The company's anesthesia depth monitor can be used to monitor the depth of anesthesia during surgery in elderly patients. The microcomputer injection pump can be used for accurate infusion and monitoring of traditional Chinese medicine solutions for clinical treatment such as post-operative analgesia, cancer pain analgesia, and tumor chemotherapy; internal heat needle therapy devices, shock wave therapy devices, etc. can all relieve chronic pain symptoms in elderly patients.
Aipeng Healthcare (300753.SZ): It accounts for a low share of Ruishenan shares and has not had an impact on the company's business
Gelonghui, March 20 | Aipeng Medical (300753.SZ) said on the investor interactive platform that the company participated in Changzhou Ruishenan Medical Devices Co., Ltd. in 2019, and the current shareholding ratio is 3.51%. Changzhou Ruishenan originated from the industry-university-research transformation of the Tsinghua University Microelectronics Institute team's implantable nerve stimulator project. The founding team graduated from Tsinghua University and was founded with the participation of Tsinghua Venture Capital and listed companies. According to data provided by Ruishenan, Ruishen's implantable closed-loop nerve stimulator system (CNS) can be used to treat various brain diseases such as Parkinson's disease, epilepsy, Alzheimer's disease, and depression. Currently
Express News | Aipeng Medical: The company's primary goal in the pain relief pump market is to reach an absolute leading position in market share
Express News | Aipeng Medical: The company is one of the few domestic enterprises that have mastered anesthesia depth index monitoring technology
Express News | Aipeng Healthcare: Currently operating normally, there is no risk of liquidating shares pledged by actual controllers
Some directors and executives of Aipeng Healthcare (300753.SZ) plan to spend a total of no less than 5.4 million yuan to increase their shareholding
Zhitong Finance App News, Aipeng Healthcare (300753.SZ) issued an announcement. Some directors and senior management of the company intend to increase their holdings of the company through centralized bidding within 6 months from the date of disclosure of this announcement. The total amount of the proposed increase is not less than RMB 5.4 million. The funds required to increase their holdings are their own capital and self-raised funds.
Aipon Healthcare (300753.SZ): 2023 pre-profit of 8 million yuan to 12 million yuan, reversing year-on-year losses
Gelonghui, January 25 | Aipeng Healthcare (300753.SZ) announced its 2023 annual performance forecast. Total operating income during the reporting period was 41 million yuan to 440 million yuan, an increase of 26.62%-35.88% over the same period of the previous year; net profit attributable to shareholders of listed companies, profit of 8 million yuan to 12 million yuan, loss of 76.3774 million yuan for the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 4 million yuan to 8 million yuan, loss for the same period last year 82.2817 million yuan. During the reporting period, the public
Aipon Medical (300753.SZ): “Norssing” nasal care sprayer can be used for nasal cleansing in patients with acute and chronic rhinitis, allergic rhinitis, sinusitis, and upper respiratory tract infections
Gelonghui, November 29丨Aipeng Medical (300753.SZ) stated on the investor interactive platform that the company's “North Clear” nasal care sprayer can be used for nasal cleansing for patients with acute and chronic rhinitis, allergic rhinitis, sinusitis, and upper respiratory tract infections. It can be used as a treatment method prescribed in hospitals, and also has the role of daily nasal washing. Numerous clinical studies and consensus have shown that nasal saline flushing can reduce viral load in the nasal cavity, effectively improve nasal symptoms, shorten the course of the disease, and accelerate recovery. The main principles are: 1. Physically remove pathogenic bacteria from the nose and reduce viral load; 2. Chloride ions and carbonic acid in sea salt water
Aipon Healthcare (300753.SZ): The anesthesia robot project is in the design and development stage
On November 24, Gelonghui (300753.SZ) stated on the investor interactive platform that the company's anesthesia robot project is in the design and development stage. The technical requirements of the project are high. Currently, the pre-set parameter requirements have been met in the simulation organization, and the performance performance in animal tissue is being further optimized. The project is progressing normally according to the company's project plan.
[Instant Analysis of BT Financial Report] Aibang Healthcare 2023 Third Quarter Report: Net profit turned loss into profit, gross margin increased significantly
Announcement time of this financial report: 2023-10-20 17:01:00 Jiangsu Aipeng Medical Technology Co., Ltd. (stock code: 300753) is a medical device company focusing on pain management and upper airway diagnosis and treatment. According to its financial report for the third quarter of 2023, the company's business performance in the field of pain management and upper airway diagnosis and treatment is steady, and its financial situation has improved markedly. First, as can be seen from the balance sheet, Aibang Medical's total assets at the end of the third quarter of 2023 were 838 million yuan, a decrease from 870 million yuan at the end of the previous year. Total liabilities were 142 million yuan, compared to
Aipeng Healthcare (300753.SZ): Plans to postpone the “Industrial Base Upgrading and Construction Project” and “R&D Center Construction Project” until December 31, 2025
Glonghui, October 20, 丨 Aipeng Healthcare (300753.SZ) announced that on October 20, 2023, the company held the 6th meeting of the 3rd board of directors and the 6th meeting of the 3rd board of supervisors, respectively to review and pass the “Proposal on the Extension of Fund-raising Investment Projects”. Based on the current implementation progress of fund-raising investment projects (“fund-raising projects”), the company extended the implementation period of the “Industrial Base Upgrade Project” and “R&D Center Construction Project” to December 31, 2025.
Aibang Healthcare (300753.SZ): Plans to use no more than 120 million yuan of idle capital raised and no more than 100 million yuan of own capital for cash management
Glonghui, Oct. 20 | Aipon Healthcare (300753.SZ) announced that the company held the 6th meeting of the 3rd board of directors on October 20, 2023 to deliberate and pass the “Proposal on Using Part of Idle Raised Funds and Idle Own Funds for Cash Management”. It was agreed that on the premise that the company does not affect normal operations and capital safety, the company will use no more than RMB 120 million (including principal amount) of idle capital raised capital and no more than RMB 100 million (including principal amount) for cash management. It is highly secure for the purchase period within 12 months (inclusive). Wealth management products with good liquidity,
Aipang Healthcare (300753.SZ) released results for the first three quarters, with net profit of 6.7978 million yuan, an increase of 113.01%
Aipon Healthcare (300753.SZ) released its report for the third quarter of 2023, and achieved revenue of 2.9 in the first three quarters...
Analysis
Price Target
No Data
